Abstract 741P
Background
Determination of the molecular subtype of endometrial cancer has been shown to be prognostic and predictive and is therefore essential for treatment decisions and prognosis prediction in endometrial cancer. Therefore, assessment of mismatch repair protein (MMR) deficiency by immunohistochemistry (IHC) and sequential microsatellite instability (MSI) in cases with indeterminate protein expression status is part of routine diagnostics in the diagnosis of endometrial cancer. Several methods are available for MSI analysis.
Methods
We compared the Idylla™ MSI Assay (Biocartis) with our institutional MSI gold standard test (Bethesda panel) and with MMR IHC in a cohort of n=332 hysterectomy specimen of endometrioid adenocarcinomas of the corpus uteri (2008-2016). MSI tests were performed according to the manufacturer's recommendations (Idylla™) and a validated internal protocol (Bethesda panel). MMR IHC was analyzed using tissue microarrays, but repeated on whole slides in case of a negative internal control or a discrepancy with the MSI test. The Idylla™ MSI results were compared with the Bethesda MSI results and the MMR-IHC.
Results
In our cohort of n=332 endometrioid endometrial cancer cases, MMR IHC, Idylla™ MSI and gold standard (Bethesda) MSI test results were evaluable in all cases, n=325, and n=324, respectively. N=87/332 (26.2%) had MMR deficiency (MMRd) with n=78/332 (23.5%) showing MLH1/PMS2 loss. The Idylla™ MSI assay revealed MSI in n=68/325 (20.9%) cases. Idylla™ results agreed with MMR IHC results in n=303/325 cases (overall percentage agreement (OPA)=93.2%; Kappa= 0.814). Bethesda results were consistent with MMR IHC results in n=310/324 cases (OPA=95.7%; Kappa= 0.884). Both Idylla™ and Bethesda MSI results were available for n=322/332 cases (97.0%) with n=308/322 concordant cases. OPA between the two MSI test methods was therefore 95.65% (Kappa= 0.874).
Conclusions
Idylla™ MSI showed a very high OPA with the gold standard MSI test and with MMR IHC. In view of its short turnaround time and ease of use, this test could therefore be an excellent alternative for MSI testing in endometrial cancer, even with old tissue samples.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Biocartis provided the cartridges free of charge.
Disclosure
R. Erber: Financial Interests, Institutional, Research Funding: Biocartis; Financial Interests, Personal, Invited Speaker: AstraZeneca. I. Unser, A. Hartmann, R. Stöhr: Financial Interests, Institutional, Research Funding: Biocartis. All other authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01